Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Future bronchodilator therapy: a bitter pill to swallow?

Identifieur interne : 001306 ( Main/Exploration ); précédent : 001305; suivant : 001307

Future bronchodilator therapy: a bitter pill to swallow?

Auteurs : Rachel L. Clifford ; Alan J. Knox

Source :

RBID : pubmed:23023969

Descripteurs français

English descriptors

Abstract

Maintenance of airway tone, prevention of airway obstruction, and acute relief from bronchospasm are key targets of asthma therapy. This role is currently performed by β-agonists. However, chronic use of β-agonists to treat asthma is associated with desensitization of β-agonist signaling and a resultant loss of bronchodilator effect, worsening of airway hyperreactivity, and increased incidence of asthma-related morbidity and mortality. There have been several attempts to identify novel non-β-agonist bronchodilators including ATP-sensitive potassium channel (K(ATP)) agonists such as cromakalim and its active enantiomer BRL-38227 and the cGMP activators atrial natriuretic peptide (ANP) and BAY 41-22722. However, these either have not made it to clinical trial, required high doses, had little effect in patients, or had a high incidence of side effects. Recent data suggests that a novel bronchodilator target exists, the bitter taste receptor TAS2R. Two recent studies [An SS, Wang WC, Koziol-White CJ, Ahn K, Lee DY, Kurten RC, Panettieri RA Jr, Liggett SB. Am J Physiol Lung Cell Mol Physiol 303: L304-L311, 2012; Pulkkinen V, Manson ML, Säfholm J, Adner M, Dahlén SE. Am J Physiol Lung Cell Mol Physiol. doi:10.1152/ajplung.00205.2012.] provide new understanding of the signaling pathways utilized by TAS2Rs to mediate their bronchodilatory effects and how TAS2R-mediated bronchodilation is affected by β-agonist signaling desensitization. As our understanding of TAS2Rs and their agonists increases, they move closer to a viable therapeutic option; however, further definition is still required and questions remain to be answered. This editorial focus discusses these studies within the context of existing literature and raises questions and challenges for the future development of bitter (better?) therapies for asthma.

DOI: 10.1152/ajplung.00303.2012
PubMed: 23023969


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Future bronchodilator therapy: a bitter pill to swallow?</title>
<author>
<name sortKey="Clifford, Rachel L" sort="Clifford, Rachel L" uniqKey="Clifford R" first="Rachel L" last="Clifford">Rachel L. Clifford</name>
</author>
<author>
<name sortKey="Knox, Alan J" sort="Knox, Alan J" uniqKey="Knox A" first="Alan J" last="Knox">Alan J. Knox</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:23023969</idno>
<idno type="pmid">23023969</idno>
<idno type="doi">10.1152/ajplung.00303.2012</idno>
<idno type="wicri:Area/PubMed/Corpus">000352</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000352</idno>
<idno type="wicri:Area/PubMed/Curation">000352</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000352</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000356</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000356</idno>
<idno type="wicri:Area/Ncbi/Merge">000185</idno>
<idno type="wicri:Area/Ncbi/Curation">000185</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000185</idno>
<idno type="wicri:Area/Main/Merge">001307</idno>
<idno type="wicri:Area/Main/Curation">001306</idno>
<idno type="wicri:Area/Main/Exploration">001306</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Future bronchodilator therapy: a bitter pill to swallow?</title>
<author>
<name sortKey="Clifford, Rachel L" sort="Clifford, Rachel L" uniqKey="Clifford R" first="Rachel L" last="Clifford">Rachel L. Clifford</name>
</author>
<author>
<name sortKey="Knox, Alan J" sort="Knox, Alan J" uniqKey="Knox A" first="Alan J" last="Knox">Alan J. Knox</name>
</author>
</analytic>
<series>
<title level="j">American journal of physiology. Lung cellular and molecular physiology</title>
<idno type="eISSN">1522-1504</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Bronchodilator Agents (pharmacology)</term>
<term>Chloroquine (pharmacology)</term>
<term>Humans</term>
<term>Male</term>
<term>Muscle Relaxation (physiology)</term>
<term>Muscle, Smooth (physiology)</term>
<term>Quaternary Ammonium Compounds (pharmacology)</term>
<term>Receptors, Adrenergic, beta-2 (metabolism)</term>
<term>Receptors, G-Protein-Coupled (agonists)</term>
<term>Receptors, G-Protein-Coupled (metabolism)</term>
<term>Respiratory Physiological Phenomena</term>
<term>Respiratory System (metabolism)</term>
<term>Tachyphylaxis (physiology)</term>
<term>Trachea (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Appareil respiratoire (métabolisme)</term>
<term>Bronchodilatateurs (pharmacologie)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Composés d'ammonium quaternaire (pharmacologie)</term>
<term>Humains</term>
<term>Muscles lisses (physiologie)</term>
<term>Mâle</term>
<term>Phénomènes physiologiques respiratoires</term>
<term>Relâchement musculaire (physiologie)</term>
<term>Récepteurs bêta-2 adrénergiques (métabolisme)</term>
<term>Récepteurs couplés aux protéines G (agonistes)</term>
<term>Récepteurs couplés aux protéines G (métabolisme)</term>
<term>Tachyphylaxie (physiologie)</term>
<term>Trachée (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en">
<term>Receptors, G-Protein-Coupled</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Receptors, Adrenergic, beta-2</term>
<term>Receptors, G-Protein-Coupled</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Bronchodilator Agents</term>
<term>Chloroquine</term>
<term>Quaternary Ammonium Compounds</term>
</keywords>
<keywords scheme="MESH" qualifier="agonistes" xml:lang="fr">
<term>Récepteurs couplés aux protéines G</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Respiratory System</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Appareil respiratoire</term>
<term>Récepteurs bêta-2 adrénergiques</term>
<term>Récepteurs couplés aux protéines G</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Bronchodilatateurs</term>
<term>Chloroquine</term>
<term>Composés d'ammonium quaternaire</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Muscles lisses</term>
<term>Relâchement musculaire</term>
<term>Tachyphylaxie</term>
<term>Trachée</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Muscle Relaxation</term>
<term>Muscle, Smooth</term>
<term>Tachyphylaxis</term>
<term>Trachea</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Humans</term>
<term>Male</term>
<term>Respiratory Physiological Phenomena</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Humains</term>
<term>Mâle</term>
<term>Phénomènes physiologiques respiratoires</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Maintenance of airway tone, prevention of airway obstruction, and acute relief from bronchospasm are key targets of asthma therapy. This role is currently performed by β-agonists. However, chronic use of β-agonists to treat asthma is associated with desensitization of β-agonist signaling and a resultant loss of bronchodilator effect, worsening of airway hyperreactivity, and increased incidence of asthma-related morbidity and mortality. There have been several attempts to identify novel non-β-agonist bronchodilators including ATP-sensitive potassium channel (K(ATP)) agonists such as cromakalim and its active enantiomer BRL-38227 and the cGMP activators atrial natriuretic peptide (ANP) and BAY 41-22722. However, these either have not made it to clinical trial, required high doses, had little effect in patients, or had a high incidence of side effects. Recent data suggests that a novel bronchodilator target exists, the bitter taste receptor TAS2R. Two recent studies [An SS, Wang WC, Koziol-White CJ, Ahn K, Lee DY, Kurten RC, Panettieri RA Jr, Liggett SB. Am J Physiol Lung Cell Mol Physiol 303: L304-L311, 2012; Pulkkinen V, Manson ML, Säfholm J, Adner M, Dahlén SE. Am J Physiol Lung Cell Mol Physiol. doi:10.1152/ajplung.00205.2012.] provide new understanding of the signaling pathways utilized by TAS2Rs to mediate their bronchodilatory effects and how TAS2R-mediated bronchodilation is affected by β-agonist signaling desensitization. As our understanding of TAS2Rs and their agonists increases, they move closer to a viable therapeutic option; however, further definition is still required and questions remain to be answered. This editorial focus discusses these studies within the context of existing literature and raises questions and challenges for the future development of bitter (better?) therapies for asthma.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Clifford, Rachel L" sort="Clifford, Rachel L" uniqKey="Clifford R" first="Rachel L" last="Clifford">Rachel L. Clifford</name>
<name sortKey="Knox, Alan J" sort="Knox, Alan J" uniqKey="Knox A" first="Alan J" last="Knox">Alan J. Knox</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001306 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001306 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23023969
   |texte=   Future bronchodilator therapy: a bitter pill to swallow?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23023969" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021